Burning Rock Biotech Limited
NASDAQ · us_market
No AI summary generated yet for this ticker.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
GUANGZHOU, China, April 28, 2026 -- Burning Rock Biotech Limited , a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that...
Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed and volumes weakening notably in the second half. On the company’s full-year results call, management
Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed and volumes weakening notably in the second half. On the company’s full-year results call, management
GUANGZHOU, China, March 12, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2025. 2025 Business Overview and Recent Updates Early Detection The core patent related to Burning Rock's proprietary ultrasensitive detection technology,
Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 81.82 percent increase over losses of $(1.10) per share from the same period last year. The company reported $18.063 million in
GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that as of the date of this press release, its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased US$811,721.28 of the Company’s ADSs from the open market, which was conducted in co
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2025 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Er
While sentiment has soured due to the ongoing sell-off in the cryptocurrency market, several notable investors have continued to accumulate Bitcoin (CRYPTO: BTC) and <
GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 23, 2025 at 10:30 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. Th
Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...
Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...
GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2025. Recent Business Updates Therapy Selection Presented study results at the Cell Reports Medicine on esophageal squamous cell carcinoma in September 2025. “Integrating ctDNA
Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is a 60 percent increase over losses of $(0.50) per share from the same period last year. The company reported $18.488 million in
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 35.4K | $571.12K | 0.00% | Added+13.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-05-30 | -13.90 | -18.10 | -30.22% |
| 2023-03-28 | -19.00 | -21.10 | -11.05% |
| 2022-11-15 | -18.80 | -23.30 | -23.94% |
| 2022-08-31 | -18.50 | -25.00 | -35.14% |
| 2022-05-31 | -17.90 | -25.00 | -39.66% |
| 2022-03-21 | -15.00 | -24.00 | -60.00% |
| 2021-11-15 | -10.25 | -16.40 | -60.00% |
| 2021-08-31 | -9.45 | -19.60 | -107.41% |
| 2021-05-25 | -9.20 | -16.50 | -79.35% |
| 2021-03-10 | -10.30 | -15.10 | -46.60% |
| 2020-11-20 | -7.60 | -12.20 | -60.53% |
| 2020-08-11 | -13.85 | -26.80 | -93.50% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BNR | -45.48% | -60.41% | -53.75% | +200.65% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -48.45% | -55.77% | -50.30% | +187.96% |